MedTrace Logo

Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease

NCT02498782 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2015-07-15

No results posted yet for this study

Summary

The hypothesis is to evaluate if the treatment with Fexinidazole will lead to a better sustained clearance of the parasites at 6 months of follow-up when in comparison to placebo in patients with chronic indeterminate CD.

Conditions

  • Chagas Disease
  • Trypanosomiasis, South American
  • South American Trypanosomiasis
  • Disease, Chagas

Interventions

DRUG

Fexinidazole

DRUG

Placebo

Sponsors & Collaborators

  • Drugs for Neglected Diseases

    lead OTHER

Principal Investigators

  • Faustino Torrico, MD · Plataforma de Antención Integral de Pacientes con Enfermedad de Chagas, Cochabamba, Bolivia

  • Joaquim Gascón, MD · Centro de Salud Internacional, Hospital Clínico de Barcelona

  • Lourdes O Daza, MD · Plataforma de Antención Integral de Pacientes con Enfermedad de Chagas, Tarija, Bolivia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-09-30
Completion
2016-02-29

Countries

  • Bolivia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02498782 on ClinicalTrials.gov